Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer: Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study - Science Daily

1. Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer: Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study  Science Daily
2. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial  The Lancet
3. View full coverage on Google News

Investigational drug with immunotherapy may provide new therapeutic opportunity for patients previously treated for kidney and lung cancer: Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase 1B study - Science Daily
Read More